Breast cancer screening 16 and cervical cancer prevention in developing countries: Strategies for the future

Breast and Gynecological Cancers: An Integrated Approach for Screening and Early Diagnosis in Developing Countries

Volumn , Issue , 2013, Pages 301-329

  Kelly, Kevin M ^a   Shetty, Mahesh K ^b   Fregnani, José Humberto Tavares Guerreiro ^c  

^a Pasadena Breast Ultrasound Center   (United States)

^b Woman's Hospital of Texas   (United States)

^c BARRETOS CANCER HOSPITAL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84906848476     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-1876-4_16     Document Type: Chapter

References (41)

1. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57(1):7-28.
2. Burchell AN, Winer RL, de Sanjose S, Franco EL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006;24 Supplement 3:S3/52-61.
3. WHO. Initiative for vaccine research (IVR)—viral cancer—HPV. World Health Organization. 2011. http://www.who.int/vaccine_research/diseases/viral_ cancers/en/index3.html. Cited 30 Jun 2012.
4. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533-43.
5. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127(12):2893-917.
6. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon: International Agency for Research on Cancer; 2011. http://globocan.iarc.fr. Cited 30 Jun 2012.
7. Update on Human Papillomavirus (HPV) Vaccines. CCDR (Canada communicable disease report) 2012;38:1-62.
8. WHO. Human papillomavirus and HPV vaccines: Technical information for policy-makers and health professionals. Geneva: WHO Press; 2007. p. 43.
9. WHO/ICO. Human papillomavirus and related cancers in world. Summary report update. October 9, 2009. WHO/ICO Information Centre on HPV and Cervical Cancer. 2009.
10. Parkin DM, Bray F. Chapter 2: The burden of HPV- related cancers. Vaccine. 2006;24 Supplement 3:S3/11-25.
11. WHO. Human papillomavirus vaccines. WHO position paper. Weekly Epidemiological Record 2009;15: 118-31.
12. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377(9783):2085-92.
13. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24.
14. FDA. Vaccines, blood & biologics. Vaccines. Approved products FDA; 2012. http://www.fda.gov/Biologics BloodVaccines/Vaccines/ApprovedProducts/ucm 172678.htm. Cited 2012 Jul 20, 2012.
15. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-43.
16. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95(11): 1459-66.
17. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19): 1915-27.
18. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374(9686):301-14.
19. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89-99.
20. Villa LL. HPV prophylactic vaccination: the fi rst years and what to expect from now. Cancer Lett. 2011;305(2): 106-12.
21. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic adrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: Aa randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271-8.
22. Stokley S, Cohn A, Dorell C, Hariri S, Yankey D, Messonnier N, et al. Adolescent vaccination-coverage levels in the United States: 2006-2009. Pediatrics. 2011; 128(6): 1078-86.
23. Finn A. Strategy options for HPV vaccine delivery in EU countries. Guidance for the introduction of HPV vaccines in EU countries. Stockholm: European Centre for Disease Prevention and Control; 2008. p. 30-6.
24. Garland SM, Skinner SR, Brotherton JM. Adolescent and young adult HPV vaccination in Australia: achievements and challenges. Prev Med. 2011;53 Supplement 1:S29-35.
25. Immunise Australia Program. Human Papillomavirus (HPV). Information about the National Human Papillomavirus (HPV) Vaccination Program funded under the Immunise Australia Program.: Australian Government. Depatment of Health and Aging; 2011 [updated Apr 04, 2011]; http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv#figure 2. Cited 30 Jun 2012.
26. Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, et al. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: First results of the VENICE2 2010 survey. Euro surveillance: Bulletin europeen sur les maladies transmissibles = European communicable disease bulletin 2010;15(47).
27. Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, HPV Vaccine: Implementation and Financing Policy. The Henry J. Kaiser Family Foundation. 2007. http://www.kff.org/womenshealth/upload/7602.pdf. Cited 2012.
28. Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, The HPV Vaccine: Access and Use in the U.S.: The Henry J. Kaiser Family Foundation. 2011. http://www.kff.org/womenshealth/7602.cfm. Cited 2012.
29. I ARC. Making cervical cancer vaccines widely available in developing countries: Cost and financing issues. IARC. http://screening.iarc.fr/doc/IAVI_ PATH_HPV_financing_brief.pdf. Cited 2012.
30. Smith LM, Brassard P, Kwong JC, Deeks SL, Ellis AK, Levesque LE. Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an Ontario cohort of grade 8 girls. BMC Public Health. 2011;11:645.
31. Colucci R, Hryniuk W, Savage C. HPV vaccination programs in Canada: Are we hitting the mark? Report Card on Cancer in Canada [Internet]. 2010 Aug 11, 2012. Available from: http://www.canceradvocacy.ca/reportcard/2008/HPV%20Vaccination%20Programs%20in%20Canada.pdf.
32. Colucci R, Hryniuk W, Savage C. Progress toward implementation of human papillomavirus vaccination--the Americas, 2006-2010. MMWR Morbidity and mortality weekly report 2011;60(40): 1382-4.
33. LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ. 2011;89(11):821-30B.
34. Saxenian H. HPV Vaccine Adoption in Developing Countries: Cost and Financing Issues: International AIDS Vaccine Initiative/Program for Appropriate Technology in Health (PATH). http://www.iavi.org/HPVreport. Cited 2007.
35. Garland SM. Human papillomavirus vaccination: Where to now? Sex Transm Infect. 2011;87 Supplement 2:1123-4.
36. GAVI Alliance. http://www.gavialliance.org/. Cited 2012.
37. GAVI. Human papillomavirus vaccine support. GAVI Alliance. http://www.gavialliance.org/support/nvs/human-papillomavirus-vaccine-support/. Cited 2012.
38. PAHO. PAHO Revolving Fund. Pan American Health Organization; Available from: http://new.paho.org/hq/index.php?option=com_content&task=view&id=1864&Itemid=2234&lang=en.
39. Bonanni P, Levi M, Latham NB, Bechini A, Tiscione E, Lai P, et al. An overview on the implementation of HPV vaccination in Europe. Hum Vaccin. 2011; 7(Supplement): 128-35.
40. Ladner J, Besson MH, Hampshire R, Tapert L, Chirenje M, Saba J. Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Public Health. 2012;12:370.
41. Ladner J, Besson MH, Hampshire R, Tapert L, Chirenje M, Saba J. GAP. Gardasil Access Program. 2012. http://www.gardasilaccessprogram.org/section/141. Cited 4 Nov 2012.